The training course is going to be delivered by Spanish top-notch representatives, professionals, and teachers from the areas of Market Access and Health Economics:
Dr. Pepi Hurtado, Partner in ilS
Dr. Pepi Hurtado has extensive experience in the pharmaceutical and biotechnology industry at global and national levels. She worked as senior consultant at IMS Health and as an independent consultant at her own company (DelScience). Prior to becoming a consultant, she had experience as a researcher both in academia and pharmaceutical industry. Additionally. Dr. Hurtado has a broad training in scientific fields, holds an MSc in Pharmacy (University of Barcelona) and a Ph.D. in Pharmaceutical Technology (University of London).
Dr. Itziar Escudero, Partner in ilS
Dr. Itziar Escudero has extensive experience in entrepreneurship, business development and strategic consulting in the pharmaceutical, biotech and medical device industries, both at national and international level. She worked for international firms such as Ernst & Young and PwC. Dr. Escudero holds an M.B.A. degree from the University of California, a Ph.D. in Biochemistry and Molecular Biology from the University of Barcelona, and a Masters in Chemical Sciences with a specialization in Biochemistry from Universidad Autónoma de Madrid.
Dr. Laura Pellisé, Senior Research Fellow at the Centre for Research in Health and Economics (CRES)
Dr. Laura Pellisé is Senior Researcher at the Centre for Research in Economics and health (CRES) at the Department of Economics and Business at Universitat Pompeu Fabra (UPF). She has a degree in Economics from Universitat de Barcelona, holds an MSc in Health Policy and Management from Harvard University and a Ph.D. in Economics from UPF.
Dr. Pellisé has been a visiting professor at the Department of Economics of Universidad Carlos III of Madrid. She also joined the Spanish Ministry of Health as a technical advisor in 1997. She held, since 2001, top management positions in the largest private hospital group in Spain, USP (now Grupo Quirón Salud), and then was managing director of the Vall d’Hebron Institute of Oncology (VHIO).
She joined the CRES at UPF in 2011, as its Director. She is member of the group of experts appointed by the European Commission for the evaluation of SME (Small Medium Enterprises) in health care. She co-directs the Master in Health Policy and Management of UPF.
Dr. Carme Pinyol, Pricing and Reimbursement and Market Access Senior Expert
Dr. Pinyol is graduated from Universitat Autònoma de Barcelona (UAB) with a degree in Medicine and Surgery and a Postgraduate in Medicine for the Pharmaceutical Industry, a Postgraduate degree in Statistical Techniques for the Life Sciences and a Postgraduate degree in clinical trial design for the life sciences. She holds a Master degree in Health Economics and Pharmacoeconomics from Universitat Pompeu Fabra (UPF), a Master degree in Social Healthcare from University of Castilla-La Mancha, an Executive Programme at ESADE, and currently she is completing her Ph.D. in Health Economics.
Dr. Pinyol, Founder and Director of INNOVA - Strategic consulting, worked for 23 years in different areas of the pharmaceutical industry (sales, training, marketing, discount medical economics, health, price and market access) and held various management positions. She was the Director of Pricing and Health Economics for two years in a multinational consultancy.
Dr Antoni Gilabert-Perramon, the Managing Director of Pharmacy and Medicines in the Catalan Health Service (Government of Catalonia).
Dr. Gilabert has an extensive trajectory in the health department based on planning and developing pharmaceutical and drug policies. He has a degree in Pharmacy from Universitat de Barcelona, holds an MSc in Health Policy and Healthcare Management and a Ph.D. in pharmacology from Universitat de Barcelona. Additionally, he collaborates in teaching and training activities organized by different international universities, schools, and health institutions.
Dr. Gilabert is currently responsible for the planning, management, control, and evaluation of the pharmaceutical, orthopedics and supplementary benefits in Catalonia.